Market Newsdesk

Worcester, MA, Feb. 23, 2021 (GLOBE NEWSWIRE) — Vystar^® Corporation (OTCQB: VYST) has named Byron Novosad, DDS, to the Vystar Board of Directors, effective immediately. He fills the seat vacated by Keith Osborn, MD, who has retired.

Steve Rotman, Vystar CEO, noted, “We are grateful to Dr. Osborn for his many years of service and his support of Vystar. He has provided excellent guidance and has been a valued sounding board for us on many areas. We wish him all the best in his retirement.”

“Dr. Novosad has supported us at critical junctures as an investor and in an advisory capacity over many years,” stated Rotman. “He will be an excellent addition to our Board, as he has an in-depth knowledge of Vystar’s businesses, our history, and vision for the future. His knowledge of the healthcare industry both as a practitioner, industry advisor and investor will be helpful for the development of our multiple health-related product lines, such as our patented RxAir^® UV light air purifiers to battle airborne Coronaviruses and other diseases, patented Vytex^® deproteinized latex and rubber for medical gloves and a wide range of products, and Fluid Energy Conversion applications.”

“As long-term shareholder and advisor to Vystar, and RxAir before its acquisition by Vystar, I have gone the extra mile to research the businesses,” stated Dr. Byron Novosad, DDS. “I have toured the rubber plantations and RxAir and Vytex factories, and have developed a thorough understanding of Vystar’s technologies. From that, I see tremendous potential. I am looking forward to playing a larger, more formal role in driving shareholder value by shaping the consistent execution and communication of Vystar’s vison, activities and achievements.”

Dr. Novosad has operated a private periodontal practice in the Houston, Texas area for 30 years, and has been a Clinical Assistant Professor of Periodontics at the Periodontal Graduate Clinic for the University of Texas Dental branch in Houston since 2007. He has served as Staff Dentist for Houston Community College School of Dental Hygiene, and was on the Advisory Board of Wharton County Jr. College School of Dental Hygiene for 37 years. He provided consulting services to the Harris County Public Health and Environmental Services Dept., UV Flu Technology (now RxAir) starting in 2011 to present, TracFind (an item tracking device), and Vystar Corp. Dr. Novosad earned his Doctor of Dental Surgery degree and Periodontics License from University of Texas at Houston.

For details on Vytex, contact [email protected] or 508-791-9114 or visit Vytex.com. Follow Vystar and Vytex news on Twitter: @VystarCompany

# # #

About Vystar Corporation:

Based in Worcester, Mass., Vystar^® Corp. (OTCQB: VYST) is the majority owner of Rotmans Furniture and Carpet and environmentally friendly technologies and products to improve lives, including RxAir^® UV light air purification products, Vytex™ Natural Rubber Latex (NRL) and Fluid Energy Solutions. Vystar is the exclusive creator of Vytex, a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, “green” and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows. For more information, visit www.vytex.com.

Contacts:

Vystar
Media: Julie Shepherd, Accentuate PR, 847 275 3643, [email protected]
Investors: Lee Howley, [email protected] 508-791-9114

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

BOCA RATON, Fla., Feb. 23, 2021 (GLOBE NEWSWIRE) — Newtek Business Services Corp., (NASDAQ: NEWT), an internally managed business development company (“BDC”), today announced that its Board of Directors declared a first quarter 2021 cash dividend of $0.50¹ per share. The first quarter 2021 dividend is payable on March 31, 2021 to shareholders of record as of March 22, 2021. The payment of the first quarter 2021 dividend would represent a 13.6% increase over the first quarter 2020 dividend of $0.44 per share, and a 25% increase over the first quarter 2019 dividend of $0.40 per share.

Note regarding Dividend Payments: The Company’s Board of Directors expects to maintain a dividend policy with the objective of making quarterly distributions in an amount that approximates 90 – 100% of the Company’s annual taxable income. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s fiscal year based upon its taxable income for the full year and distributions paid for the full year.

¹Amount and timing of dividends, if any, remain subject to the discretion of the Company’s Board of Directors. Newtek Business Services Corp., Your Business Solutions Company^®, is an internally managed BDC, which along with its controlled portfolio companies, provides a wide range of business and financial solutions under the Newtek^® brand to the small- and medium-sized business (“SMB”) market. Since 1999, Newtek has provided state-of-the-art, cost-efficient products and services and efficient business strategies to SMB relationships across all 50 states to help them grow their sales, control their expenses and reduce their risk.

Newtek’s and its portfolio companies’ products and services include: Business Lending, SBA Lending Solutions, Electronic Payment Processing, Technology Solutions (Cloud Computing, Data Backup, Storage and Retrieval, IT Consulting), eCommerce, Accounts Receivable Financing & Inventory Financing, Insurance Solutions, Web Services, and Payroll and Benefits Solutions.

Newtek

^®
and Your Business Solutions Company^®, are registered trademarks of Newtek Business Services Corp.

Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements. Words such as “believes,” “intends,” “expects,” “projects,” “anticipates,” “forecasts,” “goal” and “future” or similar expressions are intended to identify forward-looking statements.
All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the plans, intentions and expectations reflected in or suggested by the forward-looking statements. Such risks and uncertainties include, among others, intensified competition, operating problems and their impact on revenues and profit margins, anticipated future business strategies and financial performance, anticipated future number of customers, business prospects, legislative developments and similar matters. Risk factors, cautionary statements and other conditions, which could cause Newtek’s actual results to differ from management’s current expectations, are contained in Newtek’s filings with the Securities and Exchange Commission and available through

http://www.sec.gov/

. Newtek cautions you that forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those projected or implied in these statements.

SOURCE: Newtek Business Services Corp.

Investor Relations & Public Relations


Contact: Jayne Cavuoto
Telephone: (212) 273-8179 / [email protected]

TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) — Purpose Investments Inc. (“Purpose”) is thrilled to announce the TMX Group will begin listing options around Purpose Bitcoin ETF (“the ETF”) today on the Montréal Exchange. The listing of options solidifies Purpose Bitcoin ETF’s position as the leading Bitcoin ETF vehicle for both institutions and retail investors.

“This is great news for investors and a powerful display of innovation in motion,” said Som Seif, founder and CEO of Purpose Investments. “In less than a week’s time from when we launched Purpose Bitcoin ETF, we’re already seeing the infrastructure for options trading put into place by the TMX Group. Not only does this provide investors with more ways to gain exposure to Bitcoin, it also really cements the idea that Purpose Bitcoin ETF is the premier tracker of the cryptocurrency in North America.”

The initial options schedule and strike prices are as follows:

Purpose Bitcoin ETF launched February 18, 2021 and has already attracted more than $500 million of investor capital. The ETF is available in Canadian dollar-denominated units (TSX: BTCC.B) and US dollar-denominated units (TSX: BTCC.U). To learn more about the ETF, please visit https://www.purposeinvest.com/funds/purpose-bitcoin-etf

About Purpose Investments Inc.

Purpose is an asset management company with more than $10 billion in assets under management. Purpose has an unrelenting focus on client-centric innovation, offering a range of managed and quantitative investment products. Purpose is led by well-known entrepreneur Som Seif and is a division of Purpose Financial, an independent, technology-driven financial services platform which is reshaping the industry by connecting and creating opportunities across asset management, wealth management and small business financial services.

For further information please contact:
Matt Padanyi
Purpose Investments Inc.
Tel: (877) 789-1517
Email: [email protected]

Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus and other disclosure documents before investing. Investment funds are not covered by the Canada Deposit Insurance Corporation or any other government deposit insurer. There can be no assurance that the full amount of your investment in a fund will be returned to you. If the securities are purchased or sold on a stock exchange, you may pay more or receive less than the current net asset value. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

C-Bond BRS, independently validated to provide National Institute of Justice Level I, Level IIA, Level II, and Underwriters Laboratories 752 ballistic-resistant protection, has been installed by multiple major news organizations

HOUSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced that a major news network has placed an additional order for C-Bond BRS (ballistic-resistant system) for its New York office location to protect against potential gun violence and other means of forced entry.

C-Bond BRS has been installed by multiple major news organizations to protect employees at various sites in the U.S.

C-Bond BRS is a ballistic-resistant film system that consists of the patented C-Bond glass strengthening technology and security film. The C-Bond technology chemically bonds to the defects randomly distributed on the glass surface to increase impact resistance and prevent breakage. C-Bond BRS is validated by an independent third-party laboratory to provide National Institute of Justice (NIJ) Level I, Level IIA, Level II, and Underwriters Laboratories (UL) 752 ballistic-resistant protection.

“Unfortunately, recent events throughout our country have again shown the importance of protecting buildings and those inside against gun violence, riots, and those who seek to forcibly enter a facility,” stated Scott R. Silverman, Chairman and CEO of C-Bond. “C-Bond BRS provides a proven means to stop bullets from penetrating glass, and we are proud that this media organization has once again selected C-Bond BRS to help protect its employees.”

C-Bond BRS has been installed in more than 80 schools, government buildings, media sites, and other high-security facilities around the country. C-Bond’s glass strengthening technology is protected by 22 patents and patent pending applications.

About C-Bond                
C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based advanced nanotechnology company and marketer of the patented and patent-pending C-Bond technology, developed in conjunction with Rice University and independently proven to significantly strengthen glass in key automotive and structural applications. The Company’s Transportation Solutions Group sells C-Bond nanoShield, a liquid solution applied directly to automotive windshields, sold through distributors. The Company’s Safety Solutions Group sells ballistic-resistant glass solutions directly to private enterprises, schools, hospitals, and government agencies. The Company also sells disinfection products, including MB-10 Tablets. For more information, please visit our website: www.cbondsystems.com, Facebook: https://www.facebook.com/cbondsys/ and Twitter: https://twitter.com/CBond_Systems.

Forward-Looking Statements

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, C-Bond’s ability to raise capital; the Company’s ability to successfully commercialize its products; the effect of the COVID-19 global pandemic on the Company’s and its customers’ ability to operate; the Company’s ability to source materials; the Company’s ability to retain key employees and consultants; as well as other risks. Additional information about these and other factors may be described in the Company’s filings with the Securities and Exchange Commission (“SEC”) including its Form 10-K filed on March 25, 2020, its Forms 10-Q filed on November 16, 2020, August 14, 2020, and May 15, 2020, and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference.

Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, are scheduled to present on Thursday, February 25^th at 2:20pm Eastern time and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.

The live webcast of Cassava Sciences’ presentation can be accessed under the ‘Investors’ tab at www.CassavaSciences.com and will be available for replay through May 26, 2021.

About Alzheimer’s Disease

Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.¹ The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.

About Simufilam, the Company’s Lead Drug Candidate

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer’s Disease. Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimer’s disease with a simple blood test. Simufilam and SavaDx were both developed in-house. Both product candidates are substantially funded by peer-review research grant awards from the National Institutes of Health (NIH). Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third party.

About Cassava Sciences, Inc.

Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Eric Schoen, Chief Financial Officer
[email protected]
(512) 501-2450

_______________


¹

Alzheimer’s Disease International
,
Dementia Statistics
, available on-line
and accessed February 20, 2021
:

https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/